Last reviewed · How we verify
Captopril Tablets
Captopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.
Captopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure. Used for Hypertension, Heart failure, Post-myocardial infarction left ventricular dysfunction.
At a glance
| Generic name | Captopril Tablets |
|---|---|
| Also known as | Capoten |
| Sponsor | Ain Shams University |
| Drug class | ACE inhibitor |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Captopril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. By reducing angiotensin II levels, the drug causes vasodilation, decreases peripheral vascular resistance, and reduces aldosterone secretion, leading to lower blood pressure and reduced cardiac workload. This mechanism also provides cardioprotective and renoprotective effects.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction left ventricular dysfunction
- Diabetic nephropathy
Common side effects
- Cough
- Dizziness
- Hyperkalemia
- Angioedema
- Hypotension
- Taste disturbance
Key clinical trials
- Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Effect of Captopril on GLS in Duchenne Myodystrophy (EARLY_PHASE1)
- Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years (PHASE4)
- Alpha-lipoic Acid in Diabetic Nephropathy (PHASE3)
- Management of Hypertension in the Early Postpartum: a Randomized Controlled Trial (PHASE4)
- NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial (PHASE3)
- Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Captopril Tablets CI brief — competitive landscape report
- Captopril Tablets updates RSS · CI watch RSS
- Ain Shams University portfolio CI